Advertisement

Action Potential Triangulation Explains Acute Proarrhythmic Effect of Aliskiren in a Whole-Heart Model of Atrial Fibrillation

  • Christian EllermannEmail author
  • André Mittelstedt
  • Julian Wolfes
  • Kevin Willy
  • Patrick Leitz
  • Florian Reinke
  • Lars Eckardt
  • Gerrit Frommeyer
Article

Abstract

Recent experimental studies showed a protective effect of the renin inhibitor aliskiren regarding atrial structural remodeling. Purpose of this study was to assess acute electrophysiologic effects of aliskiren in a whole-heart model of atrial fibrillation (AF) and to investigate its impact on the ventricle. Twelve rabbit hearts were excised, retrogradely perfused, and paced at different cycle lengths. To enhance atrial vulnerability, a combination of acetylcholine (ACh) and isoproterenol (Iso) was infused and significantly reduced atrial action potential duration (aAPD90) and atrial effective refractory period (aERP). Additional infusion of aliskiren prolonged aAPD90 but did not alter aERP. A triangulation of action potential with ACh/Iso and a further triangulation after treatment with aliskiren were noted. Vulnerability to AF was tested by employing trains of burst pacing. Administration of ACh/Iso provoked more episodes of AF (baseline: 26 episodes, Iso/Ach: 48 episodes). Additional treatment with aliskiren induced AF significantly more often (108 episodes). Another nine hearts were perfused with aliskiren to examine its ventricular effects. Infusion with aliskiren abbreviated ventricular APD90 and ERP. Utilizing programmed ventricular stimulation, a trend towards more ventricular arrhythmias in aliskiren-treated hearts was observed. Though aliskiren did not reduce aAPD90 or aERP, acute treatment with aliskiren promoted AF. Triangulation of atrial action potentials, which is an established risk factor for ventricular proarrhythmia, may contribute to the increased atrial vulnerability. This effect may interfere with its recently demonstrated beneficial properties in atrial remodeling. Of note, aliskiren might have a proarrhythmic effect on the ventricular level.

Keywords

Aliskiren Atrial fibrillation Arrhythmia Hypertension 

Notes

Acknowledgements

This study was supported by the Hans-and-Gertie Fischer Foundation and by the German Cardiac Society (to G.F.).

Compliance with Ethical Standards

Conflict of interest

The authors report no relationships that could be construed as a conflict of interest.

Ethical Approval

All applicable international, national, and institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution at which the studies were conducted.

References

  1. 1.
    Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., et al. (2016). 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace, 18, 1609–1678.CrossRefGoogle Scholar
  2. 2.
    Musini, V. M., Lawrence, K. A., Fortin, P. M., Bassett, K., & Wright, J. M. (2017). Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database Systematic Review, 4, CD007066.Google Scholar
  3. 3.
    Satoh, A., Niwano, S., Niwano, H., Kishihara, J., Aoyama, Y., Oikawa, J., et al. (2017). Aliskiren suppresses atrial electrical and structural remodeling in a canine model of atrial fibrillation. Heart and Vessels, 32, 90–100.CrossRefGoogle Scholar
  4. 4.
    Tsai, C.-F., Chen, Y.-C., Lin, Y.-K., Chen, S.-A., & Chen, Y.-J. (2011). Electromechanical effects of the direct renin inhibitor (aliskiren) on the pulmonary vein and atrium. Basic Research in Cardiology, 106, 979–993.CrossRefGoogle Scholar
  5. 5.
    Zhao, Z., Chen, Y., Li, W., Wang, X., Li, J., Yang, W., et al. (2016). Aliskiren protecting atrial structural remodeling from rapid atrial pacing in a canine model. Naunyn Schmiedebergs Arch Pharmacol, 389, 863–871.CrossRefGoogle Scholar
  6. 6.
    Zhao, Z., Wang, X., Li, J., Yang, W., Cheng, L., Chen, Y., et al. (2014). Protective effects of aliskiren on atrial ionic remodeling in a canine model of rapid atrial pacing. Cardiovascular Drugs and Therapy, 28, 137–143.CrossRefGoogle Scholar
  7. 7.
    Yamada, C., Kuwahara, K., Yamazaki, M., Nakagawa, Y., Nishikimi, T., Kinoshita, H., et al. (2015). The renin–angiotensin system promotes arrhythmogenic substrates and lethal arrhythmias in mice with non-ischaemic cardiomyopathy. Cardiovascular Research, 109, 162–173.CrossRefGoogle Scholar
  8. 8.
    Jia, Y.-Y., Bao, Z.-W., Wei, M.-F., Zhu, J.-H., & Le, G. (2013). Aliskiren ameliorates sympathetic nerve sprouting and suppresses the inducibility of ventricular tachyarrhythmia in postinfarcted rat heart. Chinese Medical Journal (England), 126, 4707–4714.Google Scholar
  9. 9.
    Frommeyer, G., Kohnke, A., Ellermann, C., Dechering, D. G., Kochhäuser, S., Reinke, F., et al. (2017). Acute infusion of levosimendan enhances atrial fibrillation in an experimental whole-heart model. International Journal of Cardiology, 236, 423–426.CrossRefGoogle Scholar
  10. 10.
    Ellermann, C., Wolfes, J., Puckhaber, D., Bögeholz, N., Leitz, P., Lange, P. S., et al. (2018). Digitalis promotes ventricular arrhythmias in flecainide- and ranolazine-pretreated hearts. Cardiovascular Toxicology.  https://doi.org/10.1007/s12012-018-9494-7.Google Scholar
  11. 11.
    Milberg, P., Ramtin, S., Mönnig, G., Osada, N., Wasmer, K., Breithardt, G., et al. (2004). Comparison of the in vitro electrophysiologic and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block. Journal of Cardiovascular Pharmacology, 44, 278–286.CrossRefGoogle Scholar
  12. 12.
    Frommeyer, G., Milberg, P., Uphaus, T., Kaiser, D., Kaese, S., Breithardt, G., et al. (2013). Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation. Cardiovascular Therapeutics, 31, e63–e71.CrossRefGoogle Scholar
  13. 13.
    Nattel, S., Burstein, B., & Dobrev, D. (2008). Atrial remodeling and atrial fibrillation: Mechanisms and implications. Circulation: Arrhythmia and Electrophysiology, 1, 62–73.Google Scholar
  14. 14.
    Hondeghem, L., Carlsson, L., & Duker, G. (2001). Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation, 103, 2004–2013.CrossRefGoogle Scholar
  15. 15.
    Milberg, P., Hilker, E., Ramtin, S., Cakir, Y., Stypmann, J., Engelen, M. A., et al. (2007). Proarrhythmia as a class effect of quinolones: Increased dispersion of repolarization and triangulation of action potential predict torsades de pointes. Journal of Cardiovascular Electrophysiology, 18, 647–654.CrossRefGoogle Scholar
  16. 16.
    Dobrev, D., & Ravens, U. (2003). Remodeling of cardiomyocyte ion channels in human atrial fibrillation. Basic Research in Cardiology, 98, 137–148.Google Scholar
  17. 17.
    Wettwer, E., Hála, O., Christ, T., Heubach, F., Jr., Dobrev, D., Knaut, M., et al. (2004). Role of I Kur in controlling action potential shape and contractility in the human atrium: Influence of chronic atrial fibrillation. Circulation, 110, 2299–2306.CrossRefGoogle Scholar
  18. 18.
    Frommeyer, G., Kohnke, A., Ellermann, C., Dechering, D. G., Kochhäuser, S., Pott, C., et al. (2017). Experimental evidence for a severe proarrhythmic potential of levosimendan. International Journal of Cardiology, 228, 583–587.CrossRefGoogle Scholar
  19. 19.
    Vaidyanathan, S., Jarugula, V., Dieterich, H. A., Howard, D., & Dole, W. P. (2008). Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clinical Pharmacokinetics, 47, 515–531.CrossRefGoogle Scholar
  20. 20.
    Vaidyanathan, S., Jermany, J., Yeh, C., Bizot, M. N., & Camisasca, R. (2006). Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. British Journal of Clinical Pharmacology, 62, 690–698.CrossRefGoogle Scholar
  21. 21.
    Vaidyanathan, S., Camenisch, G., Schuetz, H., Reynolds, C., Yeh, C. M., Bizot, M. N., et al. (2008). Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: The role of P-glycoprotein in the disposition of aliskiren. Journal of Clinical Pharmacology, 48, 1323–1338.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Cardiology II (Electrophysiology)University Hospital MünsterMūnsterGermany

Personalised recommendations